New hope for hard-to-treat breast cancer: A166 targets tumors after other therapies fail
NCT ID NCT07299825
First seen Jan 06, 2026 · Last updated May 01, 2026 · Updated 17 times
Summary
This study tests a drug called A166 in 40 adults with HER2-positive breast cancer that has spread and no longer responds to standard treatments. Participants must have already tried a type of antibody-drug conjugate (TOP1-ADC). The goal is to see if A166 can shrink tumors or slow the cancer. This is not a cure, but aims to control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER-2 POSITIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Henan Provincial Cancer Hospital
RECRUITINGZhenzhou, Henan, 450000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.